TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.100nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Affinity DataKi: 0.100nMAssay Description:Displacement of [3H]nociceptin from human NOP receptor expressed in CHO-K1 cells by scintillation proximity assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.100nM ΔG°: -59.4kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.100nM ΔG°: -59.4kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.100nMAssay Description:The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 0.100nMAssay Description:The agonistic or antagonistic effect of the substances to be tested on the rat-species vanilloid receptor 1 (VR1/TRPV1) can be determined using the f...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 0.100nMAssay Description:The agonistic or antagonistic effect of the substances to be tested on the rat-species vanilloid receptor 1 (VR1/TRPV1) can be determined using the f...More data for this Ligand-Target Pair
Affinity DataKi: 0.190nMAssay Description:Displacement of [3H]nociceptin from human NOP receptor expressed in CHO-K1 cells by scintillation proximity assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 0.200nMAssay Description:The agonistic or antagonistic effect of the substances to be tested on the rat-species vanilloid receptor 1 (VR1/TRPV1) can be determined using the f...More data for this Ligand-Target Pair
Affinity DataKi: 0.240nMAssay Description:Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.260nMAssay Description:Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assayMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nM ΔG°: -56.5kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nM ΔG°: -56.5kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nM ΔG°: -56.5kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nM ΔG°: -56.5kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nMAssay Description:The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Affinity DataKi: 0.300nMAssay Description:Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 minsMore data for this Ligand-Target Pair
Affinity DataKi: 0.300nMAssay Description:Displacement of [3H]nociceptin from human NOP receptor expressed in CHO-K1 cells after 90 minsMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.320nMAssay Description:Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.Checked by AuthorMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 0.350nMAssay Description:The agonistic or antagonistic effect of the substances to be tested on the rat-species vanilloid receptor 1 (VR1/TRPV1) can be determined using the f...More data for this Ligand-Target Pair
Affinity DataKi: 0.360nMAssay Description:Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.390nMAssay Description:Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assayMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.398nMAssay Description:Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergineMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 0.400nMAssay Description:The agonistic or antagonistic effect of the substances to be tested on the rat-species vanilloid receptor 1 (VR1/TRPV1) can be determined using the f...More data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.400nMAssay Description:Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.Checked by AuthorMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Rattus norvegicus (rat))
Gruenenthal
US Patent
Gruenenthal
US Patent
Affinity DataKi: 0.400nMAssay Description:The agonistic or antagonistic effect of the substances to be tested on the rat-species vanilloid receptor 1 (VR1/TRPV1) can be determined using the f...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.400nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.400nM ΔG°: -55.8kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
Affinity DataKi: 0.400nMAssay Description:Displacement of [3H]nociceptin from human NOP receptor expressed in CHO-K1 cells after 90 minsMore data for this Ligand-Target Pair
Affinity DataKi: 0.400nMAssay Description:Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.5nMAssay Description:Displacement of [3H]nociceptin from human NOP receptor expressed in CHO-K1 cells after 90 minsMore data for this Ligand-Target Pair
Affinity DataKi: 0.5nMAssay Description:Displacement of [3H]nociceptin from human NOP receptor expressed in CHO-K1 cells after 90 minsMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.5nMAssay Description:Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.Checked by AuthorMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.5nM ΔG°: -55.2kJ/moleT: 2°CAssay Description:The agonistic or antagonistic effect of the substances to be tested on the vanilloid receptor 1 (VR1) can also be determined using the following assa...More data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.5nMAssay Description:Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.Checked by AuthorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.501nMAssay Description:Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergineMore data for this Ligand-Target Pair
Affinity DataKi: 0.550nMAssay Description:Displacement of [3H]nociceptin from human NOP receptor expressed in CHO-K1 cells by scintillation proximity assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.600nMAssay Description:Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 minsMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.600nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.630nMAssay Description:Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.Checked by AuthorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.630nMAssay Description:Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.Checked by AuthorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.630nMAssay Description:Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.Checked by AuthorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.630nMAssay Description:Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.Checked by AuthorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.630nMAssay Description:Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.Checked by AuthorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.630nMAssay Description:Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.Checked by AuthorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.631nMAssay Description:Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergineMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2C(Homo sapiens (Human))
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Smithkline Beecham Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.631nMAssay Description:Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergineMore data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.700nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
Affinity DataKi: 0.700nMAssay Description:Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 minsMore data for this Ligand-Target Pair